NM_015040.4:c.2993C>G

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_015040.4(PIKFYVE):​c.2993C>G​(p.Thr998Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.972 in 1,613,816 control chromosomes in the GnomAD database, including 764,069 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.93 ( 66349 hom., cov: 30)
Exomes 𝑓: 0.98 ( 697720 hom. )

Consequence

PIKFYVE
NM_015040.4 missense

Scores

17

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: -0.0190

Publications

29 publications found
Variant links:
Genes affected
PIKFYVE (HGNC:23785): (phosphoinositide kinase, FYVE-type zinc finger containing) Phosphorylated derivatives of phosphatidylinositol (PtdIns) regulate cytoskeletal functions, membrane trafficking, and receptor signaling by recruiting protein complexes to cell- and endosomal-membranes. Humans have multiple PtdIns proteins that differ by the degree and position of phosphorylation of the inositol ring. This gene encodes an enzyme (PIKfyve; also known as phosphatidylinositol-3-phosphate 5-kinase type III or PIPKIII) that phosphorylates the D-5 position in PtdIns and phosphatidylinositol-3-phosphate (PtdIns3P) to make PtdIns5P and PtdIns(3,5)biphosphate. The D-5 position also can be phosphorylated by type I PtdIns4P-5-kinases (PIP5Ks) that are encoded by distinct genes and preferentially phosphorylate D-4 phosphorylated PtdIns. In contrast, PIKfyve preferentially phosphorylates D-3 phosphorylated PtdIns. In addition to being a lipid kinase, PIKfyve also has protein kinase activity. PIKfyve regulates endomembrane homeostasis and plays a role in the biogenesis of endosome carrier vesicles from early endosomes. The protein plays a key role in cell entry of ebola virus and SARS-CoV-2 by endocytosis Mutations in this gene cause corneal fleck dystrophy (CFD); an autosomal dominant disorder characterized by numerous small white flecks present in all layers of the corneal stroma. Histologically, these flecks appear to be keratocytes distended with lipid and mucopolysaccharide filled intracytoplasmic vacuoles. [provided by RefSeq, Jul 2021]
PIKFYVE Gene-Disease associations (from GenCC):
  • fleck corneal dystrophy
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=1.6278725E-6).
BP6
Variant 2-208325804-C-G is Benign according to our data. Variant chr2-208325804-C-G is described in ClinVar as Benign. ClinVar VariationId is 333910.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.977 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_015040.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
PIKFYVE
NM_015040.4
MANE Select
c.2993C>Gp.Thr998Ser
missense
Exon 20 of 42NP_055855.2

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
PIKFYVE
ENST00000264380.9
TSL:1 MANE Select
c.2993C>Gp.Thr998Ser
missense
Exon 20 of 42ENSP00000264380.4
PIKFYVE
ENST00000443896.5
TSL:1
n.*2344C>G
non_coding_transcript_exon
Exon 19 of 19ENSP00000407692.1
PIKFYVE
ENST00000443896.5
TSL:1
n.*2344C>G
3_prime_UTR
Exon 19 of 19ENSP00000407692.1

Frequencies

GnomAD3 genomes
AF:
0.931
AC:
141355
AN:
151888
Hom.:
66297
Cov.:
30
show subpopulations
Gnomad AFR
AF:
0.803
Gnomad AMI
AF:
0.996
Gnomad AMR
AF:
0.971
Gnomad ASJ
AF:
0.996
Gnomad EAS
AF:
0.943
Gnomad SAS
AF:
0.932
Gnomad FIN
AF:
0.997
Gnomad MID
AF:
0.978
Gnomad NFE
AF:
0.983
Gnomad OTH
AF:
0.939
GnomAD2 exomes
AF:
0.965
AC:
241673
AN:
250502
AF XY:
0.966
show subpopulations
Gnomad AFR exome
AF:
0.800
Gnomad AMR exome
AF:
0.985
Gnomad ASJ exome
AF:
0.997
Gnomad EAS exome
AF:
0.940
Gnomad FIN exome
AF:
0.997
Gnomad NFE exome
AF:
0.983
Gnomad OTH exome
AF:
0.977
GnomAD4 exome
AF:
0.976
AC:
1427445
AN:
1461810
Hom.:
697720
Cov.:
77
AF XY:
0.976
AC XY:
709945
AN XY:
727210
show subpopulations
African (AFR)
AF:
0.797
AC:
26685
AN:
33468
American (AMR)
AF:
0.983
AC:
43951
AN:
44714
Ashkenazi Jewish (ASJ)
AF:
0.996
AC:
26032
AN:
26128
East Asian (EAS)
AF:
0.957
AC:
37976
AN:
39696
South Asian (SAS)
AF:
0.941
AC:
81179
AN:
86254
European-Finnish (FIN)
AF:
0.996
AC:
53193
AN:
53420
Middle Eastern (MID)
AF:
0.969
AC:
5587
AN:
5768
European-Non Finnish (NFE)
AF:
0.984
AC:
1094291
AN:
1111972
Other (OTH)
AF:
0.970
AC:
58551
AN:
60390
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.448
Heterozygous variant carriers
0
2001
4002
6004
8005
10006
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
21650
43300
64950
86600
108250
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.931
AC:
141465
AN:
152006
Hom.:
66349
Cov.:
30
AF XY:
0.933
AC XY:
69301
AN XY:
74302
show subpopulations
African (AFR)
AF:
0.803
AC:
33215
AN:
41352
American (AMR)
AF:
0.971
AC:
14843
AN:
15292
Ashkenazi Jewish (ASJ)
AF:
0.996
AC:
3449
AN:
3464
East Asian (EAS)
AF:
0.943
AC:
4857
AN:
5148
South Asian (SAS)
AF:
0.933
AC:
4491
AN:
4814
European-Finnish (FIN)
AF:
0.997
AC:
10588
AN:
10618
Middle Eastern (MID)
AF:
0.976
AC:
287
AN:
294
European-Non Finnish (NFE)
AF:
0.983
AC:
66844
AN:
68002
Other (OTH)
AF:
0.940
AC:
1983
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
448
896
1345
1793
2241
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
908
1816
2724
3632
4540
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.977
Hom.:
54269
Bravo
AF:
0.923
TwinsUK
AF:
0.987
AC:
3658
ALSPAC
AF:
0.985
AC:
3795
ESP6500AA
AF:
0.809
AC:
3564
ESP6500EA
AF:
0.982
AC:
8442
ExAC
AF:
0.960
AC:
116530
Asia WGS
AF:
0.931
AC:
3237
AN:
3478
EpiCase
AF:
0.983
EpiControl
AF:
0.985

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Mar 28, 2022
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Fleck corneal dystrophy Benign:2
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease.

Sep 05, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.074
BayesDel_addAF
Benign
-0.81
T
BayesDel_noAF
Benign
-0.79
CADD
Benign
0.97
DANN
Benign
0.29
DEOGEN2
Benign
0.14
T
Eigen
Benign
-1.5
Eigen_PC
Benign
-1.4
FATHMM_MKL
Benign
0.085
N
LIST_S2
Benign
0.095
T
MetaRNN
Benign
0.0000016
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.14
N
PhyloP100
-0.019
PrimateAI
Benign
0.29
T
PROVEAN
Benign
-0.10
N
REVEL
Benign
0.028
Sift
Benign
0.74
T
Sift4G
Benign
1.0
T
Polyphen
0.0
B
Vest4
0.025
MutPred
0.36
Loss of phosphorylation at T998 (P = 0.0717)
MPC
0.26
ClinPred
0.00051
T
GERP RS
-1.8
Varity_R
0.023
gMVP
0.11
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs893253; hg19: chr2-209190528; COSMIC: COSV104578621; API